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The complement system is a major humoral component of immunity and is
essential for the fast elimination of pathogens invading the body. In addition
to its indispensable role in innate immunity, the complement system is also
involved in pathogen clearance during the effector phase of adaptive immu-
nity. The fastest way of killing the invader is lysis by the membrane attack
complex, which is formed by the terminal components of the complement cas-
cade. Not all pathogens are lysed however and, if opsonized by a variety of
molecules, they undergo phagocytosis and disposal inside immune cells. The
most important complement-derived opsonins are C1q, the first component
of the classical pathway, MBL, the initiator of the lectin pathway and
C3-derived activation fragments, including C3b, iC3b and C3d, which all
serve as ligands for their corresponding receptors. In this review, we discuss
how complement receptors are utilized by various immune cells to tackle
invading microbes, or by pathogens to evade host response.
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The complement system consists of approximately 50
soluble, membrane-bound and regulatory proteins.
Most of the circulating, inactive complement compo-
nents are synthesized in the liver, although the local
production of complement proteins in tissues has also
been proven to play an important role in several
immune processes [1–3].
Activation of the complement cascade can occur via
the classical, the lectin-dependent or the alternative
pathway (Box 1).
Abbreviations
AIDS, acquired immune deficiency syndrome; BAD1, blastomyces adhesin 1; cC1q, collagen-like tail region of C1q; CCP, complement con-
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the immunoglobulin family; CRT, calreticulin; EBV, Epstein–Barr virus; Ecb, extracellular complement binding protein; GAS, group A Strepto-
coccus; gC1q, globular head region of C1q; GPI, glycosylphosphatidylinositol; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human
immunodeficiency virus; HSV, herpes simplex virus; HTLV-1, human T-lymphotropic virus 1; ICAM-1, intercellular adhesion molecule 1; LAD,
leucocyte adhesion deficiency; LPS, lipopolysaccharide; LTA, lipoteichoic acid; Mac, GAS Mac-1-like protein; MAC, membrane attack com-
plex; MASP, MBL-associated serine protease; MBL, mannose-binding lectin; MyD88, myeloid differentiation primary response 88; NLR,
NOD-like receptor; PfRh4, Plasmodium falciparum reticulocyte-binding-homologue-4; PMN, polymorphonuclear cells; PspA, pneumococcal
surface protein A; RCA, regulators of complement activation; Sap, secreted aspartic protease; SARS, severe acute respiratory syndrome;
SCR, short consensus repeat; SLE, systemic lupus erythematosus; TLR, Toll-like receptor; TRIF, TIR-domain-containing adapter-inducing
interferon-b; uPAR, urokinase-type plasminogen activator receptor; VSIG4, V-set and Ig domain-containing 4.
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The central event in the activation cascade is the cleav-
age of the third component, C3. Its first split products
are C3a and C3b. The small, soluble C3a peptide may
bind to G-protein-coupled C3a receptors, while the lar-
ger activation fragment C3b, containing the exposed,
reactive thioester group, has the capacity to bind cova-
lently to the activating surface on the pathogen. Cova-
lently fixed C3b is the main ligand of CR1 (CD35) and
CRIg. C3b can be further processed to generate iC3b
and C3d(g), which remain covalently attached to the
antigen and interact with complement receptors CR3
(CD11b/CD18), CR4 (CD11c/CD18), CRIg and CR2
(CD21) expressed on several cell types. In addition to
the covalently fixed C3- and C4-derived fragments, C1q
and MBL are further opsonins (Table 1, Fig. 1).
Complement receptors are essential to empower
immune cells to clear the circulation from invaders [4].
Here, we review data describing the interaction of
these receptors with different pathogens – bacteria,
viruses, fungi and parasites – mentioning also exam-
ples of how these receptors are utilized by pathogens
to evade host responses (Table 2).
Complement receptor type 1 (CR1,
CD35)
Human complement receptor type 1 (CR1, CD35) is
expressed on the surface of various myeloid and lym-
phoid cells and also on erythrocytes [5]. It is an
approximately 200 kDa single-chain transmembrane
glycoprotein with a short cytoplasmic tail. In the most
common human allotype, the extracellular portion of
the molecule is composed of 30 SCRs (Short Consen-
sus Repeat), each having 60–70 amino acids. CR1
binds activated fragments of C3 and C4, such as C3b
and C4b and with lower affinity, iC3b [6]. It is also an
important regulator of the complement cascade, since
it possesses decay-accelerating activity for the C3/C5
convertases of both the classical and alternative path-
ways. Additionally, it serves as a cofactor for Factor
I-mediated cleavage of C3b, thus blocks further activa-
tion of the complement cascade [7].
CR1 expressed by phagocytes – macrophages and
granulocytes – plays an important role in the phagocy-
tosis of C3-opsonized antigens. Its further roles include
Box 1. Activation of the complement system
The classical pathway is triggered by C1q, a subunit of the trimolecular C1 complex, upon its reaction with the Fc
portion of IgM or IgG antibodies bound to the antigen, or directly, upon recognizing pathogen surfaces and apop-
totic cells. This step is followed by the activation of C1r then C1s, the two C1q-associated serine proteases. After
cleavage of C2 and C4, the larger split products, C2b and C4b form the classical pathway’s C3 convertase on the sur-
face of the activating substance. This, in turn, activates C3, the major and central component of this cascade on
which all three complement activation pathways converge.
The lectin pathway is activated by mannose-binding lectin (MBL) and ficolins. These pattern recognition molecules
bind to microbial surface oligosaccharides and acetylated residues, and form complexes with MASP1 and MASP2,
the MBL-associated serine proteases, which cleave C2 and C4 to generate C2bC4b, the classical C3 convertase.
The alternative pathway is constitutively activated at a low level by the spontaneous hydrolysis of C3 (‘tick-over
mechanism’) in body fluids generating C3(H2O). This C3b-like molecule binds factor B, which is cleaved by the serine
protease factor D, giving rise to the formation of the initial, fluid-phase C3 convertase (C3(H2O)Bb) of the alternative
pathway. This enzyme produces further C3b fragments, resulting in a surface-bound C3bBb, the C3 convertase of the
alternative pathway. Several substances can initiate this pathway, including bacterial LPS, zymosan and biomaterials.
Of note, the alternative pathway serves as a strong amplification loop, as it can be triggered also by C3b generated
by either the classical or the lectin pathways.
The three pathways converge at the level of the central complement component, C3. Activation of this major com-
ponent leads to the generation of several biologically important C3 fragments. C3b, the first, larger cleavage product
binds covalently to the activating surface and initiates the assembly of C5 convertase enzymes of either the classical
(C4bC2bC3b) or the alternative (C3bBbC3b) pathway. Upon the cleavage of C5 by the C5 convertases, the generated
C5b binds C6 followed by the formation of the trimeric C5b-7 complex, which associates with the cell membrane. In
the next steps, the tetrameric C5b-8 complex is formed, which allows binding and polymerization of C9 molecules. In
the final step, the C5b-9 complex (MAC) inserts into the plasma membrane, which causes cell death by lysis.
Since complement activation can potentially be destructive, fluid-phase and cell membrane-bound regulators con-
trol this system to protect host tissues. These regulators of complement activation (RCA) show structural homology,
characterized by repeats of complement control protein (CCP) or sushi domains.
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transport of soluble antigen–antibody complexes from
blood to the liver [8] and inhibition of human B-cell
responses [9–12].
The expression of CR1 on human erythrocytes
was shown to vary among healthy individuals. The
CR1 gene is highly polymorphic, and an RFLP was
identified which correlates with CR1 expression levels
on RBCs. A combination of the alleles linked to
high (H) and low (L) expression levels – HH, HL
and LL, respectively – gives rise to three distinct
genotypes with high, intermediate and low expression
of CR1 [13].
Table 1. Complement receptors (For references see the text). Mo, monocyte; Mf, macrophage; DC, dendritic cell; Mast, mast cell; Bas,
basophil granulocyte; Neu, neutrophil granulocyte; Eos, eosinophil granulocyte; RBC, red blood cell; FDC, follicular dendritic cell; NK, natural
killer cell.
Name Structure Main ligand(s) Distribution Major function
cC1qR Calreticulin (CRT), 60 kDa, in
complex with CD91
Collagenous region
of C1q and MBL
Mo, Mf, DC, Mast,
Bas, B cell
Phagocytosis, Chemotaxis,
RO synthesis
gC1qR Homotrimer, 97 kDa Globular heads of
C1q and MBL
Ubiquitous Inflammation
CR1, CD35 Single chain, 200 kDa C3b, C4b Mo, Mf, Neu, Bas, Eos,
B cell, T-cell subpop,
RBC, FDC
Phagocytosis (Mf, Neu),
IC clearance, immune adherence,
antigen retention (FDC),
human B-cell inhibition
CR2, CD21 Single chain, 145 kDa in
trimolecular complex
CR2-CD19-CD81
C3d, EBV B cell, FDC Mouse B-cell coactivation,
antigen retention (FDC)
CR3, CD11b/18 Heterodimer, CD11b 170 kDa,
CD18 90 kDa
iC3b, fibrinogen, ICAM-1,
beta-glucan
Mo, Mf, DC, Neu,
B-cell subpop, FDC,
NK, platelet
Phagocytosis, RO/NO synthesis,
migration
CR4, CD11c/18 Heterodimer, CD11c 150 kDa
integrin b chain, CD18 90 kDa
iC3b, fibrinogen, ICAM-1 Mo, Mf, DC, Neu,
B-cell subpop, FDC,
NK, platelet
Adherence, migration
CRIg Ig superfamily 56 kDa iC3b, C3b Kupffer cells, subset of
tissue macrophages
Phagocytosis
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The abundance of the receptor on the surface of
various leucocytes makes these cells a potential tar-
get for intracellular pathogens. Phagocytosis – a cru-
cial step in pathogen neutralization, regulating
inflammation and antigen presentation – can be
hijacked by microbes. Pathogens are able to adhere
to or enter monocytes, macrophages and neutrophils
via phagocytic receptors, while avoiding intracellular
enzymatic digestion and subsequently contributing to
disease development. Polymorphisms of CR1 have
been linked to greater susceptibility to certain infec-
tions as well.
Viruses
Interaction between HIV (human immunodeficiency
virus) and various immunocytes, as well as red blood
cells, suggests a complex pathomechanism. Comple-
ment alone can target the virus to erythrocyte CR1,
and antibodies only enhanced this effect [14]. Viral
adherence was shown to be inhibited in the absence of
complement, while undisturbed without IgG. Further-
more, blocking CR1 significantly diminished HIV
adhesion. These experiments indicate that adherence of
the virus to red blood cells is a complement-dependent
phenomenon [15].
Fig. 1. Ligand specificity and microbial utilization of complement receptors. C1q may opsonize microbial surfaces directly or indirectly, via
binding to the Fc region of bound antibodies. The globular head of C1q may interact with gC1qR, while its collagen-like tail binds to cC1qR.
MBL directly bound to microbial surfaces presumably interacts with cC1qR. Complement activation leads to the deposition of complement
fragments that are potent ligands for several complement receptors. The larger C3b fragment is recognized by CR1 and CRIg, the
inactivated iC3b fragment interacts with CRIg, CR3 and CR4, whereas C3d is a ligand for CR2. Complement receptors interact with
pathogens through the opsonins or by direct binding of microbial components. The viruses, bacteria, fungi and parasites utilizing these
receptors are listed below the illustration.
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Monocytes and macrophages also contribute to the
progression of AIDS, as they express CD4 that HIV
uses to enter these cells. In addition, it has been shown
that the opsonization of HIV-1 and HIV-2 strains with
complement results in higher and earlier productive
infection – independently of CD4 – while blocking of
CR1 (or CR3) attenuates the enhancing effect of com-
plement [16]. The immune complex formation of virus
envelope protein-specific antibodies and HIV-1 leads
to opsonization and binding to CR1 on K562 leukae-
mia-derived cell line [14].
Certain human T lymphocyte subsets express CR1
(and CR2) receptors [17,18], making them suitable for
complement-induced immune responses, but on the
other hand, they become potential targets for infec-
tion. Similarly to monocytes and macrophages,
opsonization of HIV-1 with complement leads to ear-
lier and enhanced infection of CD4-expressing human
T-cell lines in a CR1- or CR2-dependent manner, as
blocking either of these receptors diminished the
positive effect of complement [19]. Certain HIV strains
require no involvement of CD4 in the process of CR1-
and CR2-mediated contagion of T cells. In addition to
its crucial role in linking opsonized HIV to T lympho-
cytes, CR1 presumably facilitates viral attachment to
CR2 by its cofactor activity during cleavage of C3b
into smaller fragments that could interact with CR2
[19].
The genotype of CR1 could be a major factor in
viral infections. Namely, severe acute respiratory syn-
drome (SARS) disease progression differs in patients
with or without the high expression genomic type
(HH) [20]. In the early stages of SARS disease, the
number of CR1 receptors on RBCs decreases signifi-
cantly but later returns close to physiological values.
This phenomenon may have an impact on disease pro-
gression. While patients bearing HH and HL geno-
types showed temporary reduction of CR1 levels,
SARS patients with LL genotype had no change in
their CR1 expression on erythrocytes, although this
Table 2. List of pathogens binding to various complement receptors.
Receptor Viruses Bacteria Parasites and Fungi
cC1qr–C1q Salmonella typhimurium [133]
Streptococcus pneumoniae [132]
Schistosoma mansoni [140]
cC1qr–MBL Ebola virus [120]
Human immunodeficiency virus (HIV) [119,124–126]
Herpes simplex virus (HSV) [123]
Human T-lymphotropic virus 1 (HTLV-1) [125]
Influenza A virus [122,127–129]
Severe acute respiratory syndrome (SARS-CoV) [121]
Salmonella montevideo [138,139]
Staphylococcus aureus [135–137]
Leishmania major [141]
Leishmania mexicana [141]
gC1qr Hepatitis C virus (HCV) [130,131] Staphylococcus aureus (SpA) [134]
CR1 Epstein–Barr virus (EBV) [21]
Human immunodeficiency virus (HIV) [14–16]
SARS-virus [20]
Francisella tularensis [25]
Mycobacterium leprae [30,31]
Mycobacterium tuberculosis [29]
Salmonella typhi [28]
Staphylococcus aureus (Ecb) [26]
Streptococcus pneumoniae [27]
Leishmania major [37,38]
Plasmodium falciparum
(PfRh4) [32–35]
Trypanosoma cruzi [36]
CR2 Epstein–Barr virus (EBV) [21,39–43]
Human immunodeficiency virus (HIV) [19,22]
CR3/CR4 Dengue fever virus [51]
Hantavirus [53]
Human immunodeficiency virus (HIV-1) [46–48]
Rotavirus [52]
West Nile virus [49,50]
Borrelia burgdorferi [59]
Escherichia coli [54]
Francisella tularensis [25,63]
Legionella pneumophila [65]
Listeria monocytogenes [61]
Mycobacterium kansasii [60]
Mycobacterium leprae [30]
Mycobacterium tuberculosis [55]
Porphyromonas gingivalis [66–69]
Salmonella enterica [58]
Staphylococcus aureus [56,57]
Streptococcus pneumoniae [64]
Plasmodium falciparum [78]
Leishmania ssp.[80–82]
Aspergillus fumigatus [74]
Blastomyces dermatitidis [73]
Cryptococcus neoformans [70]
Candida albicans [54,75–78]
Histoplasma capsulatum [71,72]
CRIg Adenovirus [89]
Hepatitis B virus (HBV) [95,96]
Listeria monocytogenes [85,99]
Staphylococcus aureus [85]
Candida albicans [97,98]
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might be a result of the small sample size, according
to the authors. Thus, the correlation between the geno-
type of CR1 and progression of the SARS disease is
not clear yet, but the dynamic change in the CR1
numbers during infection suggests its involvement in
the process [20].
CR2 (CD21) was formerly considered the sole recep-
tor for the major Epstein–Barr virus (EBV) glycopro-
tein gp350/220 [21]; however, there are data on EBV
patients deficient in CR2 indicating an alternative
CR2-independent process for viral entry. Experiments
with CD21- B-cell lines showed gp350/220 binding to
CR1. In the presence of HLA type II complexes in the
membrane, CR1 could mediate infection [22].
Bacteria
It is long known that CR1, in cooperation with CR3,
has a major role in the phagocytosis of opsonized par-
ticles [23,24]. For instance, Schwartz et al. [25] demon-
strated that neutrophils mediate the internalization of
opsonized Francisella tularensis via CR1 and CR3.
During bacterial colonization, different ‘strategies’
allow survival and spreading depending on whether
the species is extra- or intracellular. For example, eva-
sion of phagocytosis can be beneficial for extracellular
pathogens, while intracellular organisms can utilize
phagocytic receptors for invasion, simultaneously
inhibiting cytoplasmic killing mechanisms.
During Staphylococcus aureus infection, bacterial
ligand Ecb (extracellular complement binding protein)
has been shown to bind C3b and block direct interac-
tion between the soluble form of CR1 (sCR1) and
C3b. Thus, Ecb reduces cofactor activity of sCR1 in
the process of proteolytic inactivation of C3b [26].
CR1 expressed in the membrane of neutrophils can
also be utilized by S. aureus where Ecb binds to C3b
and prevents CR1 engagement, resulting in impaired
phagocytosis [26].
Pneumococcal surface protein A (PspA) has been
shown to interfere with complement deposition onto
Streptococcus pneumoniae. Results of a mouse study
revealed that PspA impairs mouse CR1/2-, as well as
CR3-, and CR4-mediated protection against pneumo-
coccal infection, since the bacterial protein modulates
opsonization by the components of the alternative
pathway [27].
Intracellular survival of Salmonella typhi has been
observed in human macrophages, and CR1 – along
with CR3 – was found to be involved in its internaliza-
tion. Correlation between CR1 mediated recognition
of the bacteria and survival rate has been found as
well [28].
Patients with Mycobacterium tuberculosis infection
were shown to have more circulating immune com-
plexes, a lower expression of CR1 on erythrocytes and
a higher prevalence of the HH genotype than in
healthy donors. The presence of the H allele of the
Cr1 gene may contribute to higher susceptibility to
pulmonary tuberculosis [29].
CR1 and CR3 blocking reduced adherence and
phagocytosis of Mycobacterium leprae by monocytes
[30], while CR1 polymorphisms have also been associ-
ated with the infection. Susceptibility to leprosy is
affected by the amount of soluble CR1 in blood which
competes with cell membrane receptors for pathogen
binding, subsequently affecting phagocytosis [31]. The
uptake of opsonized M. leprae is enhanced in the case
of a CR1 variant with a hidden cleavage site that
results in a lower concentration of sCR1 or a polymor-
phism that leads to an elevated level of CR1 produc-
tion [31].
Parasites
In the case of malaria, caused by the intracellular par-
asite Plasmodium falciparum, CR1 receptors expressed
on infected red blood cells can presumably facilitate
the infection by rosetting with uninfected erythrocytes
[32]. This process correlates with the severity of the
disease [33]. CR1 possibly serves as a point of entry
for the obligate intracellular pathogen during erythro-
cyte invasion. PfRh4 (P. falciparum reticulocyte-bind-
ing-homologue-4) is a major Plasmodium ligand
associated with sialic acid-independent invasion of red
blood cells. Its recognition site has been located at the
distal amino terminus of CR1 [34]. Simultaneous
engagement of CR1 by C4b and PfRh4 specifically
inhibits the receptor’s convertase decay-accelerating
activity [34]. Moreover, sCR1 was also shown to bind
PfRh4, resulting in the blocking of Plasmodium attach-
ment to erythrocyte CR1 [35], demonstrating that CR1
has a complex role in disease progression.
Soluble CR1 can also be associated with infections
with intracellular parasite Trypanosoma cruzi, responsi-
ble for Chagas disease (CD). Patients with chronic CD
have a decreased amount of sCR1 compared to
healthy controls. Certain haplotypes of CR1 have been
linked to augmented risk of T. cruzi infection and
developing chronic chagasic cardiomyopathy [36].
CR1 is a major receptor on macrophages for the
obligate intracellular protozoa Leishmania major.
Simultaneously blocking CR1 and CR3 significantly
decreases pathogen attachment, and CR1 inhibition
alone leads to attenuated binding. Data suggest higher
survival rate when pathogens enter via CR1 [37,38].
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Complement receptor type 2 (CR2,
CD21)
In humans, CR2 (CD21) is composed of 16 SCRs, a
transmembrane domain and a short cytoplasmic tail.
The protein is encoded by the CR2 gene, which is sep-
arate from the CR1 receptor coding gene, CR1. Con-
trarily, in mice both CR1 and CR2 are encoded by the
same gene (Cr2) and alternative splicing gives rise to
the two protein products. Thus, mouse CR2 is nearly
identical to CR1 both in function and structure. CR2
binds fragment C3d, the final cleavage product of C3.
CR2 has also been shown to serve as a receptor for
viruses.
Viruses
A large body of evidence indicates that CR2 mediates
EBV infection of human B lymphocytes via binding of
a virus outer membrane glycoprotein, gp350/220
[21,39–43].
C3b-opsonized HIV was shown to bind to erythro-
cyte CR1 [14,15] that is followed by the cleavage of
C3b to iC3b and C3d. This way C3d-bearing HIV tar-
gets CR2-expressing B cells and facilitates the B cell-
mediated transmission of opsonized HIV to T cells
[19,44].
Complement receptors CR3 (CD11b/
CD18) and CR4 (CD11c/CD18)
Complement receptors CR3 (aMb2, CD11b/CD18,
Mac-1) and CR4 (aXb2, CD11c/CD18, p150,95) are
members of the b2-integrin family, expressed on most
white blood cells. Both receptors bind multiple ligands
– for example iC3b, fibrinogen, ICAM-1 or pathogen-
related ligands like LPS – and thereby play an impor-
tant role in phagocytosis, adherence and migration.
Although it is clear that the two receptors exhibit
nonoverlapping functions, comparative studies are
barely available [45]. CR3 and CR4 are important
phagocytic receptors, leading either effective antimicro-
bial responses against pathogens or noninflammatory
phagocytosis of apoptotic cells under physiological
conditions of a healthy individual. Some pathogens
however evolved to hijack these functions of CR3 and
CR4. Extracellular pathogens are likely to avoid
phagocytosis by these receptors, by blocking their
function or even cleaving them from the surface of
phagocytes. In contrast, intracellular pathogens often
use them as an effective entry route into host cells,
thereby causing a more severe infection.
Viruses
As viruses are obligate intracellular pathogens, they
can benefit from their ability to exploit complement-
mediated phagocytosis. For instance, the opsonization
of HIV-1 by complement causes an up to 10-fold
higher productive infection of human dendritic cells
compared to nonopsonized or only antibody-opsonized
virus particles. Complement-dependent HIV infection
is mediated by CR3 [46], which also modulates the sig-
nal transduction of Toll-like receptor 8 (TLR8).
Modulated TLR8 signalling resulted in a lower expres-
sion of antiviral and inflammatory factors such as IL-
1b, IL-6, TNF-a, IFN-b, myxovirus resistance protein
A and IFN-stimulated genes, leading to enhanced
infection [47,48]. In addition, CR3 has been shown to
mediate the complement-dependent enhancement of
West Nile virus replication in mouse macrophages
[49,50], and the infection of human monocytes with
the Dengue fever virus [51]. The capsid of Rotavirus
contains integrin ligand motif bearing viral peptides,
which are shown to bind to b1 and b2 integrins includ-
ing CR4, and thereby promoting viral entry to host
cells [52]. A recent experiment suggests that comple-
ment receptors CR3 and CR4 also act as Hantavirus
entry receptors [53].
Bacteria
As phagocytic receptors, both CR3 and CR4 have
antimicrobial roles during the immune response to
infections. Both CR3 and CR4 are involved in the
uptake and killing of Escherichia coli [54] or M. tuber-
culosis [55]. Out of the two receptors, CR3 was shown
to be the dominant mediator of phagocytosis over
CR4 in the case of iC3b opsonized S. aureus on
human monocytes, neutrophils, monocyte-derived
macrophages and dendritic cells [56,57]. CR3 is also
involved in the phagocytosis of Salmonella enterica
[58], Borrelia burgdorferi [59] or Mycobacterium kansa-
sii [60], and has a key role in the effective immune
response against Listeria monocytogenes [61].
Phagocytosis via CR3 and CR4 is an effective
antimicrobial immune response; however, some patho-
gens try to evade it. For instance, Group A Strepto-
coccus (GAS), avoids phagocytosis by secreting the
CR3 homologue GAS Mac-1-like protein (Mac). The
Mac binds to CD16 (FccRIII) on the surface of
human polymorphonuclear cells (PMNs) and blocks
receptor–antibody interactions as well as the binding
of iC3b to CD11b, as CR3 and CD16 are physically
and functionally linked. By that Mac inhibits
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opsonophagocytosis and also the production of reac-
tive oxygen species, thereby decreasing pathogen kill-
ing [62].
While some pathogens evolved the ability to avoid
phagocytosis, others use this mechanism to enter host
cells. As CR3 and CR4 have a main role in noninflam-
matory phagocytosis of apoptotic cells, it is an ideal
target for intracellular pathogens to exploit for their
entry, especially if additional danger signals are
blocked by the microbe.
Uptake of F. tularensis, which is one of the most viru-
lent pathogens known, is mediated by CR3 and CR4 in
human dendritic cells. The internalization of F. tularensis
is followed by its rapid growth inside cells resulting in
cell death [63]. The same receptors are involved in the
infection of human macrophages, while in human neu-
trophils it is mediated by CR1 and CR3 [25].
The RrgA adhesin containing pili of Str. pneumoniae
enhances the CR3 dependent uptake of pneumococci
by murine and human macrophages through a direct
interaction with CR3. Macrophages harbouring higher
numbers of viable bacteria are more likely to be
destroyed prior to the complete eradication of the
ingested particles. Moreover, the interaction between
RrgA and CR3 leads to increased motility and migra-
tory behaviour of macrophages, resulting in an earlier
onset of septicaemia and a more rapid disease progres-
sion [64].
The obligate intracellular pathogen M. leprae invades
host cells via phagocytosis and proliferates within
mononuclear phagocytes. Both CR3 and CR4 (and
CR1) were shown to be involved in that process [30].
The causative agent of Legionnaires’ disease,
Legionella pneumophila, multiplies in human mono-
cytes and alveolar macrophages. CR1 and CR3 were
shown to mediate the adherence of Leg. pneumophila,
thereby contributing to the entry and intracellular pro-
liferation of the bacteria, as these processes could be
inhibited by specific antibodies for CR1 and CR3 [65].
Hajishengallis et al. described in detail the immune
evasion mechanism of Porphyromonas gingivalis. The
fimbriae of this bacteria serve as a ligand for CR3,
which mediates its phagocytosis, thus proactively pro-
moting its binding and entry into the host cells. The
fimbriae activate the high-affinity conformation of
CR3, which does not promote the killing but the per-
sistence of Po. gingivalis after internalization and
induces a selective suppression of IL-12 production
[66–68]. Therefore, Po. gingivalis enhances its survival
by exploiting CR3, as pharmacological blockade of
CR3 promotes its killing and suppresses Po. gingivalis-
induced periodontal bone loss in a mouse model
[66,69].
Fungi
CR3 and CR4 were shown to be involved in the bind-
ing of Cryptococcus neoformans [70] and are dominant
receptors in the uptake and killing of Candida albicans
[54]. However, the fungal pathogen Histoplasma capsu-
latum evades antimicrobial defences and proliferates
intracellularly in macrophages infected through CR3,
CR4 and LFA-1. The host macrophages are destroyed
by the multiplying yeast, and the released microbes are
phagocytosed by other macrophages attracted to the
infected site [71]. The major H. capsulatum ligand for
CR3 on macrophages was identified as heat shock pro-
tein 60 (hsp60), whereas dendritic cells recognize it via
a different ligand [72]. Similar to H. capsulatum, the
related dimorphic fungal pathogen Blastomyces der-
matitidis also expresses a CR3-interacting protein,
BAD1 (blastomyces adhesin 1). BAD1 helps pathogen
survival by binding via CR3 and CD14 that mediates
its internalization and the suppression of TNF-a pro-
duction of host cells [73].
The fungal pathogen Aspergillus fumigatus avoids
opsonization and phagocytosis by expressing proteases
that degrade complement proteins and CR3 [74]. As
surface-bound factor H can enhance the antifungal
activity via binding to CR3 and CR4, C. albicans
avoid phagocytosis by releasing the secreted aspartic
protease 2 (Sap2) to cleave both FH and the comple-
ment receptors CR3 and CR4 on macrophages [75].
Additionally, C. albicans expresses a CR3-like struc-
ture that mediates adhesion of the yeast to human
endothelium [76–78].
Parasites
CR3 and CR4 also contribute to the phagocytosis of
P. falciparum-infected erythrocytes [79], and Leishma-
nia ssp. are able to enter and survive in host macro-
phages in a CR3-mediated manner [80,81]. Moreover,
Leishmania is known to inhibit IL-12 production in
macrophages [82], which is also mediated by CR3, as
signalling via CR3 by L. major reduces IL-12 produc-
tion [83]. At the same time, dendritic cells were shown
to take up L. major in a CR3-independent, FccRI-
and FccRIII-mediated manner, which leads to a more
effective antigen presentation, indicating that CR3-me-
diated uptake is likely to represent a ‘decoy’ mecha-
nism for this pathogen [84].
CRIg
The complement receptor immunoglobulin [CRIg, also
known as V-set and Ig domain-containing 4 (VSIG4)
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and Z39Ig] is a phagocytic receptor expressed on
macrophage subpopulations. First, Helmy et al.
proved the expression of CRIg in CD68+ Kupffer cells
in the liver, interstitial macrophages in the heart, adre-
nal gland macrophages, alveolar macrophages, Hof-
bauer cells, synovial macrophages and lamina propria
histiocytes by immunohistochemistry [85]. In dendritic
cells, two groups showed the expression of CRIg, but
only at the mRNA level [86,87]. CRIg belongs to the
immunoglobulin (Ig) superfamily. In humans, it has
two splice variants. The long form (huCRIg(L)) con-
tains a V- and a C2-type Ig domain, and a short form
(huCRIg(S)) encodes only a V-type Ig domain [88].
The murine muCRIg receptor comprises only of a sin-
gle V-type Ig domain [85].
CRIg binds C3b and iC3b, providing the first line of
defence in the liver and spleen by quickly eliminating
opsonized pathogens. This receptor was shown to
swiftly resurface through recycling endosomes after
internalization, thus providing the means for a contin-
uous phagocytosis [85]. In contrast to CR3 and CR4,
which also bind iC3b-opsonized particles, CRIg is
regarded to have an anti-inflammatory role as well. It
is hypothesized that Kupffer cells internalize opsonized
microbes and apoptotic cells first through CRIg, with-
out the induction of inflammation [89,90]. A higher
number of microbial agents in the blood will prompt
the engagement of other pattern recognition and com-
plement receptors, leading to the initiation of an
immune response including leucocyte recruitment and
inflammation.
CRIg is additionally involved in the promotion of
immunological tolerance through the inhibition of the
alternative complement pathway convertases [91,92]
and the suppression of T-cell activation. However, the
tolerogenic function of CRIg might support the pro-
gression of cancer with keeping T cells in an unrespon-
sive state [93,94]. Recently, the downregulation of
CRIg in chronic Hepatitis B virus (HBV) infection was
shown to lead to a poor prognosis in hepatocellular
carcinoma patients probably due to reduced virus
clearance [95,96].
Studies on the CRIg-mediated phagocytosis proved
that this receptor is indispensable in the rapid internal-
ization of complement opsonized Adenovirus particles
[89], S. aureus [85], Li. monocytogenes [85] and C. albi-
cans [97,98]. The intracellular pathogen Li. monocyto-
genes survive inside macrophages by delaying
phagosome maturation and escaping into the cyto-
plasm [99]. Kim et al. proved a multistep counter
mechanism involving the engagement of CRIg. Sig-
nalling through CRIg facilitates phagosome acidifica-
tion and fusion with lysosomes, enhancing the killing
of internalized bacteria [100]. In addition, the ligation
of CRIg with opsonized Li. monocytogenes or an ago-
nistic mAb induces autophagosome formation,
enabling macrophages to eliminate cytoplasmic bacte-
ria already escaped from the phagolysosome system
[101].
Zeng et al. [102] proposed that the CRIg receptor is
able to clear bacteria directly without opsonization,
through the recognition of the gram-positive wall con-
stituent, lipoteichoic acid (LTA). However, Broadley
et al. [103] proved in a C3 knockout mouse, that
Kupffer cells still internalize both gram-positive and
gram-negative bacteria strains, but instead of CRIg,
they use pattern recognition receptors, that is scav-
enger receptors for LTA. Further studies are required
to clarify the individual participation of complement
and pattern recognition receptors expressed by Kupffer
cells, with consideration of the shear stress conditions
present in the liver [104].
Receptors for C1q and MBL
C1q and MBL are soluble recognition molecules,
which may serve as opsonins. Their structure is
described briefly in Box 2. Binding of these comple-
ment proteins to pathogens may either mediate their
direct uptake via their receptors expressed by phago-
cytes – including dendritic cells, macrophages and
PMNs, or may initiate the complement cascade, result-
ing in the fixation of C3- and C4-derived fragments,
leading to an enhanced engulfment of the microbe [5].
The attachment of C1q or MBL to microbial sur-
faces causes conformational changes in these mole-
cules, which subsequently initiate functions such as
complement activation and interaction with C1q or
MBL binding molecules leading to the uptake of the
microbe. MBL can act as a direct opsonin for
microbes through interaction with a cellular receptor
or binding protein [108,109]. The immunological sig-
nificance of MBL as an opsonin was established in
studies of MBL-deficient children with an opsonic
defect [110].
Several cell membrane molecules have been shown
to increase the binding of collectins and the struc-
turally related C1q, including CD93 (C1qRp), CD35
(CR1) and cC1qR (calreticulin, CRT) in complex with
CD91. Receptors for both the collagen-like tail
(cC1qR) and globular head regions (gC1qR) of C1q,
as well as receptors for MBL, have been proposed
(Table 1, Fig. 1) [111–117]. The best-accepted candi-
date is cC1qR, a protein nearly identical with CRT,
which is in complex with CD91. CRT, a chaperone
and Ca2+-binding, ubiquitous intracellular protein, is
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found in the membrane of cellular organelles, on the
cell surface, and it can also be released as a soluble
protein. It is unclear how CRT may become associated
with the cell surface, but together with CD91, surface
CRT is involved in the uptake and removal of cell
remnants when opsonized with C1q [117]. gC1qR is
specific to the globular head region, gC1q [115].
C1qRp – also known as the AA4 antigen in rodents –
enhances the uptake of C1q-opsonized particles and is
recognized by antibodies against CD93 [118].
In the next paragraphs, the biological consequences
of the interaction of C1q and MBL and their receptors
with various pathogens are summarized.
Viruses
MBL was shown to bind to HIV, SARS-CoV, Ebola,
Herpes simplex virus (HSV) and influenza virus. Sub-
sequent conformational changes of MBL were demon-
strated to allow the molecule to initiate viral
neutralization or kill them via complement activation
and opsonization [119–123].
The direct interaction of C1q and MBL was studied
in detail in the case of HIV [124] and Human
T-lymphotropic virus 1 (HTLV-1) [125,126]. The
importance of MBL in opsonizing HIV was proved by
the finding that the uptake of the opsonized virus by
tissue macrophages leads to clearance of the virus
from the blood [119].
Binding of MBL to Influenza A virus was shown to
involve the CRD domain of the molecule and man-
nose oligosaccharides of the viral haemagglutinin and
neuraminidase [127–129]. Interestingly, this interaction
was found to result in virus inactivation in a comple-
ment activation independent way [129].
Hepatitis C virus core protein interaction with the
gC1q receptor can contribute to the pathogenesis of
multiple diseases associated with HCV infection
[130]. Waggoner and colleagues demonstrated that
binding of the HCV core protein to gC1qR on
human monocyte-derived dendritic cells inhibited
TLR-induced IL-12 production but not the produc-
tion of other TLR-induced cytokines [131]. In addi-
tion, HCV core protein engagement of gC1qR on
dendritic cells promoted the production of Th2
cytokines such as IL-4 by cocultured CD4+ T cells.
These results suggest that the engagement of gC1qR
on dendritic cells by HCV limits the induction of a
Th1 response [131].
Bacteria
Agarwal et al. [132] demonstrated that the adherence
of Str. pneumoniae is facilitated by the interaction of
C1q collagen region with cC1qR resulting in an
enhanced invasion of host epithelial and endothelial
cells.
Using recombinant forms of the globular head
regions of C1q, it was found that LPS derived from
Salmonella typhimurium interacts specifically with the
B-chain of the gC1q domain in a calcium-dependent
manner. Since the LPS and the IgG-binding sites are
overlapping, binding of the bacterium can modulate
classical pathway activation [133].
In the case of S. aureus, the staphylococcal protein
A (SpA) has been shown to bind to the gC1qR,
which is highly expressed on the surface of activated
platelets and endothelial cells [134]. The bacterium
itself, however, was shown to bind MBL via peptido-
glycan and lipoteichoic acid [135,136], and MBL was
found to direct the bacterium to the phagosome
[137].
It has been described that MBL served alone as an
opsonin in the phagocytosis of Salmonella montevideo
by PMNs [138]. However, when MBL binds to CR1, it
cooperates with FccRs in the process of the phagocy-
tosis of Sa. montevideo by PMNs, as described by
Ghiran et al. [139].
Box 2. Structure of C1q and MBL complexes
C1q, a subunit of the C1 complex, is a 460 kDa hex-
americ glycoprotein containing 18 polypeptide chains
(A, B and C), which build up 6 identical units. The
tulip-like structure possesses a globular head region
(gC1q), a neck region and a collagen-like tail (cC1q)
[105]. The globular heads bind to the Fc region of
antigen-bound IgG or IgM, and it can also recognize
various structures present on self, nonself and altered
self molecules. In addition to these capacities, C1q has
a distinguished role in clearing apoptotic cells, and
therefore, C1q deficiency may provoke autoimmunity
like SLE [106].
MBL, the pattern recognition molecule of the lectin
pathway, is composed of three identical monomeric
subunits of 32 kDa glycoproteins, forming 3–6 tri-
mers. The bouquet-like structure of this collectin is
mainly held together via disulphide bonds, similarly to
that of complement C1q. Each polypeptide consists of
a carbohydrate recognition domain (CRD), a neck
domain and a collagen domain. MBL, a member of
the collectin family, is important in host defence, espe-
cially in early childhood, when the adaptive immune
response has not fully developed [107].
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Parasites
C1q has been proven to enhance eosinophil mediated
killing of schistosomula of Schistosoma mansoni [140].
Binding of MBL to L. major and Leishmania mexicana
promastigotes by mannose-containing lipophosphogly-
can was described by Green et al. [141] They suggested
that MBL may opsonize the major developmental
stages of Leishmania parasites.
Crosstalk of complement receptors
with other cell-membrane proteins
Pathogens invading the body may get opsonized by
plasma proteins other than complement – including
antibodies, pentraxins [129] and fibronectin – further-
more, microbes contain a wide variety of PAMPS. All
of these factors allow the interaction of the pathogens
with more than one receptor on the interacting
immune cell, providing an additional level of regula-
tion. Still, in most studies only the effect of single
receptor–ligand interactions is dissected (Fig. 2).
In addition to complement proteins, pathogen pat-
terns can be recognized by several innate receptor fam-
ilies, such as C-type lectin receptors (CLR), NOD-like
receptors (NLR) or Toll-like receptors (TLR). The
complex microbial surfaces offer multiple binding sites
for these receptors, which modulate host-cell response.
Both synergistic and antagonistic interactions have
been described for complement receptors and TLRs
[142].
In the next paragraph, some examples of the cooper-
ation between complement receptors and other sensors
of nonopsonized and Ig-opsonized microbes are
described briefly.
CR1-BCR
Simultaneous engagement of CR1 and BCR via com-
plement opsonized antigens can significantly alter B-
cell responses. Previously, our group was the first to
show that in human system CR1 is a potent inhibitor
of BCR-dependent B-cell activation – such as prolifer-
ation, cytokine and antibody production of cells – in
both physiological and pathological conditions [9–12].
Since then the inhibitory function of CR1 was con-
firmed by others, using in vivo model systems as well
[143–145].
CR1-TLR7, TLR9-BCR
In physiological and pathological conditions, when
both complement and TLR activating microbial
products are present in the B-cell environment, the
interaction between the two innate sensory systems has
the potential to fundamentally alter or fine-tune B-cell
responses. It has been shown recently that CR1 clus-
tering has no effect on the TLR7-induced activation of
tonsillar B cells. However, the TLR9-dependent
responses of these cells were significantly and dose-
dependently reduced by CR1 ligation [12]. These
observations highlight diverse mechanisms of the inter-
play between CR1 and TLR7 or CR1 and TLR9, in
regulating humoral immune responses.
CR2-BCR
In mouse system, it is well accepted that C3d-op-
sonized antigens, which crosslink CR2 with the BCR,
augment antibody production by several order of mag-
nitudes. Therefore, C3d is known as a molecular adju-
vant with a capacity to bridge innate and adaptive
immune responses [146]. However, in the case of
human B cells the enhancement of antibody produc-
tion by the C3-derived ligand has not been proven so
far.
CR3-FccRII, FccRIII
Zhou and Brown reported that human neutrophils pla-
ted on a surface coated with both anti-CR3 and anti-
FccRIII antibodies, exert a strong respiratory burst.
They showed that the lectin-like site of CR3, which is
sensitive to saccharides, binds to the extensively glyco-
sylated FccRIIIB molecule. Furthermore, it has also
been demonstrated that coligation of FccRIII is
required for the tyrosine phosphorylation of FccRII.
Thus, the cooperation of these three receptors leads to
the FccRII-dependent assembly of the NADPH oxi-
dase [147].
CD14-TLR4-CR3
Hawley et al. [59] demonstrated that CD14, the GPI-
linked LPS receptor expressed by phagocytes and CR3
are not associated under resting conditions; however,
their interaction is rapidly induced in the presence of
LPS, when they colocalize within lipid rafts.
Perera et al. [148] observed a combined participation
of CR3, CD14 and TLR4 in the response to LPS and
taxol, suggesting the formation of a receptor complex
of these molecules on the surface of mouse macro-
phages. Later Han et al. [149] showed that TLR4 sig-
nalling activates CR3, which in turn provides negative
feedback by enhancing the phosphorylation and subse-
quent degradation of TLR signalling molecules,
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MyD88 and TRIF. This inhibitory effect of CR3 was
also proved for the TLR7/8-induced inflammatory
response on human macrophages [150].
uPAR-CR3
The most studied interaction between integrins and
GPI-linked proteins involves the urokinase-type plas-
minogen activator receptor (uPAR; CD87) [151]. This
receptor is expressed on a wide variety of cell types,
including neutrophils and activated monocytes. uPAR-
mediated calcium signalling was observed in the pres-
ence of CR3, while it did not occur in cells of leuco-
cyte adhesion deficiency (LAD) patients or in normal
neutrophils treated with anti-CR3 mAb. It has also
been shown that complex formation with uPAR facili-
tates the adhesive functions of CR3 [152].
CR3-CR4
Our group found a division of work between CR3 and
CR4 in the process of the phagocytosis of iC3b-op-
sonized S. aureus. In the case of monocyte-derived
macrophages, we observed that blocking CR4 only
decreased the amount of surface-bound particles,
whereas internalization and digestion of the particles
were dependent on CR3. While CR4 participates in
the binding of iC3b-opsonized S. aureus, further steps
leading to the digestion of the coccus are mediated by
CR3 [56].
MBL-TLR2
MBL binds to the surface of S. aureus through lipotei-
choic acid (LTA) that is also the ligand of TLR2/6. Ip
et al. [137] showed that the presence of S. aureus
Fig. 2. Crosstalk between complement receptors and other host-cell membrane proteins induced by encountering pathogens. Crosstalk through
direct association or via signalling cascade intersection has been described for complement receptors. The presence of pathogen-associated
molecular patterns (PAMP) and opsonins on microbial surfaces promotes the simultaneous engagement of pattern recognition, complement, Fc-
receptors and the BCR. CR3 may associate with FccRIIIB and uPAR, and in the presence of LPS, it forms a complex with TLR4 and CD14. In
macrophages, there is a division of labour between CR3 and CR4 in the binding and internalization of iC3b-opsonized particles. MBL and TLR2/6
both bind the bacterial lipoteichoic acid (LTA) and become associated in the phagosomes after internalization. The cooperation between CR1 and
TLR7 or TLR9 inhibits human B-cell functions. In mouse, C3d-opsonized antigens crosslink CR2 with the BCR, which augments B-cell activation.
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induced the association of MBL and TLR2 in phago-
somes, and this interaction resulted in an enhanced
inflammatory response.
Conclusion
The complement system is a major component of
innate immunity, which contributes to the maintenance
of host homeostasis. The activation of the complement
cascade generates various biologically active comple-
ment protein-derived polypeptides that opsonize
pathogens. Complement receptors interacting with
these polypeptides are expressed by several cell types –
including monocytes, macrophages, dendritic cells,
neutrophil granulocytes, and T and B lymphocytes.
Engagement of the receptors leads to a wide array
of responses, in many cases leading to the elimination
of viruses, bacteria, fungi and parasites. On the other
hand, pathogens utilize the same receptors to evade
recognition and elimination. Learning more about the
interaction and crosstalk between cells and microbes
will help develop vaccines and treatment of
infections.
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